Glembatumumab vedotin

From WikiMD.org
Jump to navigation Jump to search

Glembatumumab vedotin (pronunciation: glemba-TOO-muh-mab vee-DOH-tin) is a monoclonal antibody-drug conjugate used in the treatment of certain types of cancer.

Etymology

The name "Glembatumumab vedotin" is derived from the components of the drug. "Glembatumumab" refers to the monoclonal antibody that targets the protein GPNMB, which is overexpressed in certain cancers. "Vedotin" refers to the cytotoxic drug that is attached to the antibody, which works by disrupting the growth of cancer cells.

Usage

Glembatumumab vedotin is used in the treatment of melanoma and breast cancer that overexpress the protein GPNMB. It works by binding to the GPNMB protein on the surface of cancer cells and delivering the cytotoxic drug directly to the cells, causing them to die.

Related Terms

  • Monoclonal antibody: A type of protein made in the lab that can bind to substances in the body, including cancer cells.
  • GPNMB: A protein that is overexpressed in certain types of cancer.
  • Cytotoxic drug: A medication that kills cells, especially cancer cells.
  • Melanoma: A type of skin cancer.
  • Breast cancer: A type of cancer that forms in the cells of the breasts.

See Also

External links

Esculaap.svg

This WikiMD dictionary article is a stub. You can help make it a full article.


Languages: - East Asian 中文, 日本, 한국어, South Asian हिन्दी, Urdu, বাংলা, తెలుగు, தமிழ், ಕನ್ನಡ,
Southeast Asian Indonesian, Vietnamese, Thai, မြန်မာဘာသာ, European español, Deutsch, français, русский, português do Brasil, Italian, polski